A Phase 3 interventional study of Certican® and Neoral in Renal Interstitial Fibrosis, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in France. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-03-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Recently, early biomarkers of renal interstitial fibrosis have been identified, amongst them de novo expression of vimentin by tubular epithelial cells, which is an intermediate filament, and the translocation of beta-catenin into their cytoplasm. These markers, when present, suggest that the epithelial cell undergoes a phenomenon well known as "epithelial to mesenchymal transition" (EMT) and could behaves like a myo-fibroblast. EMT is highly instrumental in several models of tissue fibrosis, including in the kidney. Actually, it has not only been demonstrated that these markers are detectable in the renal graft at an early time point post-transplant (i.e. as soon as three months), but also that the intensity of their expression correlates with the progression of interstitial fibrosis of the graft between 3 and 12 months
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Randomization criteria:
Eligibility criteria (no later than 4 months post-transplantation:
Non-eligibility criteria (no later than 4 months post-transplantation):
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®.
Drug: Certican® · Drug: Myfortic · Drug: Simulect® · Drug: Corticosteroids
Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®.
Drug: Certican® · Drug: Myfortic · Drug: Simulect® · Drug: Corticosteroids
Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®.
Drug: Neoral · Drug: Myfortic · Drug: Simulect® · Drug: Corticosteroids
Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®.
Drug: Neoral · Drug: Myfortic · Drug: Simulect® · Drug: Corticosteroids
Certican® was supplied to the participating centers by Novartis for the whole duration of the study in the form of tablets containing 0.75, 0.5 and 0.25 mg and packaged in blister packs.
Also known as: Everolimus, RAD001
Neoral® was also supplied to participating centers for the entire duration of the study in the form of soft capsules of 10 mg, 25 mg, 50 mg and 100 mg, and packaged in blister packs.
Also known as: Cyclosporine
Myfortic ® was supplied to the participating centers for the duration of the study in the form of 180 and 360 mg gastro-resistant, film-coated tablets. Myfortic® treatment was provided to patients preoperatively or within 24 hours post-transplantation according to the practices of the center. The starting dose was generally 1,440 mg/day, in 2 daily oral fractions, administered at 12 hour intervals up to randomization. Depending on the practices of the center and for the first 6 weeks post-transplantation, a maximum daily dose of 2160 mg of Myfortic® could be administered. In the Neoral® group, the daily dose of 1440 mg was maintained throughout the study. In the Certican® group, the dose was halved (i.e. 720 mg/day) on introducing Certican® and maintained at 720 mg/day until the end of the study. An increase in the daily dose of Myfortic® (in the Certican® group) was not authorized unless this was a temporary increase that did not exceed a period of 14 consecutive days.
The administration of Simulect® was part of the standard immunosuppressant therapy. This induction therapy was provided to patients in the form of commercial ampoules each containing 20 mg. Simulect® was administered to each patient at the dose of 20 mg on D0 and D4 post-transplantation.
Also known as: basiliximab
An intravenous steroid treatment could be administered peri or intraoperatively according to local practice at each center. Oral steroid treatment was quickly introduced (in the week following transplantation) at a daily dose of 20 mg and was then reduced and continued throughout the study at a minimum dose of 5 mg/day.
Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population
Progression of Interstitial Fibrosis/Tabular Atrophy (IF/TA) is the percentage (%) of participants with an increase \>= 1 in IF/TA grade according to Banff (2005 - 2007)according to Epithelial-mesenchymal transition (EMT) profile and by treatment groups. Grade I (the better): mild interstitial fibrosis and tubular atrophy (\<25% of cortical area) Grade II : moderate interstitial fibrosis and tubular atrophy (26-50% of cortical area) Grade III (the worse) : severe interstitial fibrosis and tubular atrophy (\>50% of cortical area)
Time frame: Month 3 (M3) and Month 12 (M12) post transplantation
Interstitial Fibrosis/Tabular Atrophy (IF/TA)
Incidence and severity of IF/TA according to 2005/2007 Banff classification system grades (grades l to lll). IF/TA grade was assessed during centralized reading according to the Banff 2005/2007 classification comprising grade I (\<25%), grade II (25-50%) and grade III (\>50% of lesions).
Time frame: M3 and M12 post transplantation
Change in Interstitial Fibrosis/Tabular Atrophy (IF/TA) Grade
Difference (M12 - M3) in IF/TA grade. IF/TA grade was assessed during centralized reading according to the Banff 2005/2007 classification comprising grade I (\<25%), grade II (25-50%) and grade III (\>50% of lesions).
Time frame: M3 and M12 post transplantation
Risk Factors of IF/TA Progression
Composite factors regarding fibrosis progression at 12 months using a logistic regression model; the parameters initially considered concerned the demographic characteristics of both recipient and donor, transplantation characteristics, hypertension, diabetes, study treatments, immunosuppression, EMT, IF/TA, function at M3, the onset of acute rejection, the presence of anti-donor antibodies at M12, infections and BK virus viremia. Arteriolar hyaline thickening is thickening of the walls of arterioles by the deposition of homogeneous pink hyaline material. BPAR is biopsy proven acute rejection. TEM progression is the increase ≥ 1 of TEM score between Month 3 and Month 12
Time frame: M12 post transplantation
Change in Percentage of Interstitial Fibrosis (IF) by Numerical Quantification
Percentage of IF measured by numerical quantification. The IF percentage was transposed in grade according to the following rule: grade 0 for an IF % ≤5%, grade I for an IF % ranging from \>5% to \< 25%, grade II for an IF % ranging from 25 to 50%, grade III for an IF % \>50%. Interstitial graft fibrosis has been identified as the primary cause of graft loss following death with a functional graft \[3-5\].
Time frame: M3 and M12 post transplantation
Number of Participants With Progression of Renal Fibrosis Using Numerical Quantification
Comparisons according to epithelial-mesenchymal transition (EMT) profile and immunosuppressive treatment
Time frame: M3 to M12 post transplantation
Number of Participants With Epithelial-mesenchymal Transition (EMT) Status
Incidence and severity of EMT status. EMT status was determined centrally using the graft biopsy taken at 3 months. The result was quickly obtained (within 7 to 15 days) and sent to the company in charge of randomization in order to allocate each patient to a treatment group and to provide the investigator with this information without confirming EMT status.
Time frame: M3 and M12 post transplantation
Number of Participants With Epithelial-mesenchymal Transition (EMT) Score
Incidence and severity of EMT score. The intensity of EMT markers expression present and detectable in the renal graft at an early stage following transplantation is known as EMT score. EMT score 0 (the best): \<1 EMT score 1 (the better): 1-10% of tubular atrophy EMT score 2: 10-25% of tubular atrophy EMT score 3: 25-50% of tubular atrophy EMT score 4 (the worst): \>50% of tubular atrophy
Time frame: M3 and M12 post transplantation
Change in EMT Score
Change (M12 - M3) in EMT Score. Progression in EMT score is defined as an increase by \>=1 of EMT score from M3 to M12. EMT score 0 (the best): \<1 EMT score 1 (the better) : 1-10% of tubular atrophy EMT score 2 : 10-25% of tubular atrophy EMT score 3 : 25-50% of tubular atrophy EMT score 4 (the worst): \>50% of tubular atrophy
Time frame: M3 and M12 post transplantation
Incidence (Number) of Subclinical Rejections and Borderline Lesions
Incidence of subclinical rejections and borderline lesions with regards to histological evidence of rejection with clinical findings. Subclinical rejections: rejection without clinical symptoms which is diagnosed by chance when a graft biopsy is performed. Clinically suspected BPAR: rejection suspected because of the presence of clinical symptoms (fever, pain, increase of creatinine) and then confirmed by the graft biopsy. Borderline lesions: suspicious for acute T-cell mediated rejection. This category is used when no intimal arteritis is present, but there are foci of tubulitis with minor interstitial infiltration or interstitial infiltration with mild tubulitis.
Time frame: M3
Change From Baseline (M3) in Estimated Glomerular Filtration Rate (eGFR)
eGFR was calculated according to the abbreviated Modification of Diet in Renal Disease (MDRD) Formula and creatinine clearance according to the Cockcroft-Gault formula (mL/min/1.73m²). LOCF = Last observation carried forward
Time frame: M3 (baseline) to M12 post transplantation
Change in Estimated Glomerular Filtration Rate (eGFR) at M12 From Baseline (M3) - ANCOVA Model
The average patient renal function was evaluated on the basis of eGFR was calculated according to the abbreviated MDRD formula and creatinine clearance according to the Cockcroft-Gault formula (mL/min/1.73m²).
Time frame: Baseline (M3), M12
Change in Urine Protein/Creatinine Ratio (Without Imputation)
One of the factors associated with EMT progression between M3 and M12 according to univariate analysis (ITT biopsies M3 \& M12).
Time frame: Month 3 (baseline), Month 12
Treatment Failures
A treatment failure is defined as biopsy proven acute rejection (BPAR), a graft loss, a death or a loss to follow up. It was assessed between randomization and 6 and 12 months post-transplantation.
Time frame: M6 and M12 post transplantation
Type of Biopsy Proven Acute Rejection (BPAR)
A biopsy proven acute rejection (BPAR) is defined as a biopsy graded IA, IB, IIA, IIB or III as per 2005/2007 Banff histological classification system. Biopsy graded IA: Significant interstitial infiltration (\> 25% of parenchyma) and foci of moderate tubulitis (\> 4 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IB: Significant interstitial infiltration (\> 25% of parenchyma) and foci of severe tubulitis (\> 10 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IIA: Mild to moderate intimal arteritis. Biopsy graded IIB: Severe intimal arteritis comprising \> 25% of the lumenal area. Biopsy graded III: Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation).
Time frame: M6 and M12 post transplantation
Severity of BPAR
A biopsy proven acute rejection (BPAR) is defined as a biopsy graded IA, IB, IIA, IIB or III as per 2005/2007 Banff histological classification system. Biopsy graded IA: Significant interstitial infiltration (\> 25% of parenchyma) and foci of moderate tubulitis (\> 4 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IB: Significant interstitial infiltration (\> 25% of parenchyma) and foci of severe tubulitis (\> 10 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IIA: Mild to moderate intimal arteritis. Biopsy graded IIB: Severe intimal arteritis comprising \> 25% of the lumenal area. Biopsy graded III: Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation).
Time frame: M6 and M12 post transplantation
Incidence (Number) of BPAR
A biopsy proven acute rejection (BPAR) is defined as a biopsy graded IA, IB, IIA, IIB or III as per 2005/2007 Banff histological classification system.
Time frame: M6 and M12 post transplantation
Incidence (Number) of Participants With Graft Losses
If a participant underwent a graft nephrectomy, then the day of nephrectomy was considered as the day of graft loss.
Time frame: M6 and M12 post transplantation
| Milestone | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- |
|---|---|---|---|---|
| Started | 36 | 60 | 39 | 59 |
| Exposed | 36 | 60 | 39 | 59 |
| Month 3 (m3) biopsies | 36 | 59 | 39 | 59 |
| Month 12 (m12) biopsies | 26 | 43 | 32 | 53 |
| M3 and m12 biopsies | 26 | 43 | 32 | 53 |
| Completed | 27 | 43 | 34 | 54 |
| Not completed | 9 | 17 | 5 | 5 |
Progression of Interstitial Fibrosis/Tabular Atrophy (IF/TA) is the percentage (%) of participants with an increase \>= 1 in IF/TA grade according to Banff (2005 - 2007)according to Epithelial-mesenchymal transition (EMT) profile and by treatment groups. Grade I (the better): mild interstitial fibrosis and tubular atrophy (\<25% of cortical area) Grade II : moderate interstitial fibrosis and tubular atrophy (26-50% of cortical area) Grade III (the worse) : severe interstitial fibrosis and tubular atrophy (\>50% of cortical area)
| Participants | Certican EMT+ | Neoral EMT+ |
|---|---|---|
| Participants with an IF/TA grade <= II at M3 | 26 | 31 |
| Participants with Fibrosis progression, M3 to M12 | 12 | 16 |
Incidence and severity of IF/TA according to 2005/2007 Banff classification system grades (grades l to lll). IF/TA grade was assessed during centralized reading according to the Banff 2005/2007 classification comprising grade I (\<25%), grade II (25-50%) and grade III (\>50% of lesions).
| Number of participants | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- |
|---|---|---|---|---|
| Interstitial Fibrosis/Tubular Atrophy (IF/TA) | 13 | 38 | 13 | 44 |
| IF/TA grade at M3 at grade 1 | 11 | 5 | 17 | 9 |
| IFTA grade at M3 at grade II | 2 | 0 | 1 | 0 |
| IF/TA grade at M3 at grade III | 0 | 0 | 1 | 0 |
| IF/TA grade at M12 at grade 0 | 9 | 20 | 7 | 31 |
| IT/TA grade at M12 at grade I | 8 | 18 | 15 | 15 |
| IF/TA grade at M12 at grade II | 6 | 5 | 9 | 6 |
| IF/TA grade at M12 at grade III | 3 | 0 | 1 | 1 |
Difference (M12 - M3) in IF/TA grade. IF/TA grade was assessed during centralized reading according to the Banff 2005/2007 classification comprising grade I (\<25%), grade II (25-50%) and grade III (\>50% of lesions).
| Number of Participants | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- |
|---|---|---|---|---|
| Difference in IF/TA grade -1 | 5 | 1 | 7 | 2 |
| Difference in IF/TA grade 0 | 9 | 21 | 9 | 33 |
| Difference in IF/TA grade 1 | 7 | 18 | 11 | 13 |
| Difference in IF/TA grade 2 | 3 | 3 | 5 | 5 |
| Difference in IF/TA grade 3 | 2 | NA | 0 | NA |
Composite factors regarding fibrosis progression at 12 months using a logistic regression model; the parameters initially considered concerned the demographic characteristics of both recipient and donor, transplantation characteristics, hypertension, diabetes, study treatments, immunosuppression, EMT, IF/TA, function at M3, the onset of acute rejection, the presence of anti-donor antibodies at M12, infections and BK virus viremia. Arteriolar hyaline thickening is thickening of the walls of arterioles by the deposition of homogeneous pink hyaline material. BPAR is biopsy proven acute rejection. TEM progression is the increase ≥ 1 of TEM score between Month 3 and Month 12
| Participants | Yes- Fibrosis Progression | No- No Fibrosis Progression |
|---|---|---|
| Donor Sex - Male | 45 | 48 |
| Donor Sex - Female | 22 | 38 |
| Donor Age - <=50 years | 28 | 48 |
| Donor Age - >50 years | 39 | 38 |
| Expanded Criteria donor: NO | 40 | 63 |
| Expanded Criteria Donor: Yes | 27 | 23 |
| Delayed graft function: No | 52 | 76 |
| Delayed graft function: Yes | 15 | 10 |
| CC at M3 <50 mL/min/1.73m^2 | 40 | 35 |
| CC at M3 >=50 mL/min/1.73m^2 (n=67, 85) | 27 | 50 |
| Mesangial matrix increase at M3 - 0 (n=64, 85) | 59 | 84 |
| Mesangial matrix (mm) increase at M3: 1 (n=64, 85) | 2 | 1 |
| Mesangial matrix increase at M3: 2 (n=64, 85) | 3 | 0 |
| Interstitial fibrosis (ci) at M3: 0 (n=66, 85) | 52 | 55 |
| Interstitial fibrosis (ci) at M3: 1 (n=66, 85) | 14 | 27 |
| Interstitial fibrosis (ci) at M3: 2 (n=66, 85) | 0 | 3 |
| Arteriolar hyaline thickening (ah) at M3: 0 | 36 | 56 |
| Arteriolar hyaline thickening (ah) at M3: 1 | 15 | 21 |
| Arteriolar hyaline thickening (ah) at M3: 2 | 10 | 8 |
| Arteriolar hyaline thickening (ah) at M3: 3 | 6 | 1 |
| BPAR - No | 55 | 79 |
| BPAR - Yes | 12 | 7 |
| TEM Progression fron M3-M12: No (n=67, 83) | 26 | 57 |
| TEM Progression fron M3-M12: Yes (n=67, 83) | 41 | 26 |
| TEM Progression fron M3-M12: Missing (n=67, 83) | 0 | 3 |
Percentage of IF measured by numerical quantification. The IF percentage was transposed in grade according to the following rule: grade 0 for an IF % ≤5%, grade I for an IF % ranging from \>5% to \< 25%, grade II for an IF % ranging from 25 to 50%, grade III for an IF % \>50%. Interstitial graft fibrosis has been identified as the primary cause of graft loss following death with a functional graft \[3-5\].
| Percentage of IF | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- |
|---|---|---|---|---|
| Percentage of IF at M3 (n=26,43,32,53) | 22.8 ± 8.9 | 15.9 ± 7.5 | 23.4 ± 9.5 | 17.8 ± 8.2 |
| Percentage of IF at M12 (n=24,42,32,53) | 27.6 ± 12.2 | 20.9 ± 10.1 | 27.4 ± 11.5 | 20.4 ± 9.1 |
| Change in Percentage of IF (n=24,42,32,53) | 5.1 ± 12.4 | 4.9 ± 12.2 | 3.9 ± 12.3 | 2.7 ± 9.7 |
Comparisons according to epithelial-mesenchymal transition (EMT) profile and immunosuppressive treatment
| Participants | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- |
|---|---|---|---|---|
| Fibrosis Progression - No (n=24, 42, 31, 53) | 18 | 30 | 19 | 42 |
| Fibrosis progression - Yes (n=24, 42,31,43) | 6 | 12 | 12 | 11 |
| Fibrosis progression - Missing (n=24, 42, 31, 53) | 2 | 1 | 0 | 0 |
Incidence and severity of EMT status. EMT status was determined centrally using the graft biopsy taken at 3 months. The result was quickly obtained (within 7 to 15 days) and sent to the company in charge of randomization in order to allocate each patient to a treatment group and to provide the investigator with this information without confirming EMT status.
| Participants | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- |
|---|---|---|---|---|
| EMT Status at M3-Negative (n=26,43,32,53) | 0 | 43 | 0 | 53 |
| EMT Status at M3- Positive (n=26,43,32,53) | 26 | 0 | 32 | 0 |
| EMT Status at M3 - Not done (n=26,43,32,53) | 0 | 0 | 0 | 0 |
| EMT Status at M12- Negative (n=25,41,32,53) | 8 | 24 | 9 | 36 |
| EMT Status at M12- Positive (n=25,41,32,53) | 17 | 17 | 23 | 17 |
| EMT Status at M12- Not done (n=25,41,32,53) | 0 | 0 | 0 | 0 |
Incidence and severity of EMT score. The intensity of EMT markers expression present and detectable in the renal graft at an early stage following transplantation is known as EMT score. EMT score 0 (the best): \<1 EMT score 1 (the better): 1-10% of tubular atrophy EMT score 2: 10-25% of tubular atrophy EMT score 3: 25-50% of tubular atrophy EMT score 4 (the worst): \>50% of tubular atrophy
| participants | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- |
|---|---|---|---|---|
| EMT Score 0 at M3 (n= 26,43,32, 53) | 0 ± 0.49 | 26 ± 0.49 | 0 ± 0.72 | 28 ± 0.5 |
| EMT Score 1 at M3 (n= 26,43,32, 53) | 0 | 17 | 0 | 25 |
| EMT Score 2 at M3 (n= 26,43,32, 53) | 17 | 0 | 20 | 0 |
| EMT Score 3 at M3 (n= 26,43,32, 53) | 9 | 0 | 8 | 0 |
| EMT Score 4 at M3 (n= 26,43,32, 53) | 0 | 0 | 4 | 0 |
| EMT Score 0 at M12 (n= 25,41,32, 53) | 1 ± 1.06 | 13 ± 1.17 | 0 ± 1.02 | 19 ± 1.03 |
| EMT Score 1 at M12 (n= 25,41,32, 53) | 7 | 11 | 9 | 17 |
| EMT Score 2 at M12 (n= 25,41,32, 53) | 10 | 11 | 10 | 12 |
| EMT Score 3 at M12 (n= 25,41,32, 53) | 4 | 4 | 9 | 4 |
| EMT Score 4 at M12 (n= 25,41,32, 53) | 3 | 2 | 4 | 1 |
| EMT Missing Score at M12 (n= 25,41,32, 53) | 1 | 2 | 0 | 0 |
Change (M12 - M3) in EMT Score. Progression in EMT score is defined as an increase by \>=1 of EMT score from M3 to M12. EMT score 0 (the best): \<1 EMT score 1 (the better) : 1-10% of tubular atrophy EMT score 2 : 10-25% of tubular atrophy EMT score 3 : 25-50% of tubular atrophy EMT score 4 (the worst): \>50% of tubular atrophy
| scores on a scale | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- |
|---|---|---|---|---|
| Change in EMT Score | -0.3 ± 1.22 | 0.9 ± 1.09 | -0.3 ± 1.05 | 0.6 ± 0.99 |
Incidence of subclinical rejections and borderline lesions with regards to histological evidence of rejection with clinical findings. Subclinical rejections: rejection without clinical symptoms which is diagnosed by chance when a graft biopsy is performed. Clinically suspected BPAR: rejection suspected because of the presence of clinical symptoms (fever, pain, increase of creatinine) and then confirmed by the graft biopsy. Borderline lesions: suspicious for acute T-cell mediated rejection. This category is used when no intimal arteritis is present, but there are foci of tubulitis with minor interstitial infiltration or interstitial infiltration with mild tubulitis.
| Participants | Certican | Neoral |
|---|---|---|
| Subclinical rejections-No (n=68, 84) | 67 | 84 |
| Subclinical rejections- Yes (n=68, 84) | 1 | 0 |
| Subclinical rejections- missing (n=68, 84) | 1 | 1 |
| Clinically suspected BPAR - No (N=68, 84) | 68 | 84 |
| Clinically suspected BPAR - Yes (N=68, 84) | 0 | 0 |
| Clinically suspected BPAR - Missing (N=68, 84) | 1 | 1 |
| Borderline lesions - No (n=68,84) | 62 | 71 |
| Borderline lesions - Yes (n=68,84) | 6 | 13 |
| Borderline lesions - Missing (n=68,84) | 1 | 1 |
eGFR was calculated according to the abbreviated Modification of Diet in Renal Disease (MDRD) Formula and creatinine clearance according to the Cockcroft-Gault formula (mL/min/1.73m²). LOCF = Last observation carried forward
| mL/min/1.73m^2 | Certican | Neoral |
|---|---|---|
| without imputation | 6.99 ± 1.66 | 2.54 ± 1.5 |
| imputation by LOCF(96, 97) | 5.96 ± 1.39 | 2.15 ± 1.37 |
The average patient renal function was evaluated on the basis of eGFR was calculated according to the abbreviated MDRD formula and creatinine clearance according to the Cockcroft-Gault formula (mL/min/1.73m²).
| mL/min/1.73m² | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- |
|---|---|---|---|---|
| without imputation | 8.6 ± 15.21 | 5.6 ± 18.73 | 1.5 ± 9.49 | 3.8 ± 10.99 |
| imputation by LOCF (36, 60, 39, 58) | -11.9 ± 27.78 | 27.3 ± 138.44 | 5.1 ± 40.80 | -4.9 ± 29.09 |
One of the factors associated with EMT progression between M3 and M12 according to univariate analysis (ITT biopsies M3 \& M12).
| mg/mmol | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- |
|---|---|---|---|---|
| Change in Urine Protein/Creatinine Ratio (Without Imputation) | 44.4 ± 188.99 | 3.5 ± 48.37 | 16.0 ± 41.53 | 29.8 ± 189.41 |
A treatment failure is defined as biopsy proven acute rejection (BPAR), a graft loss, a death or a loss to follow up. It was assessed between randomization and 6 and 12 months post-transplantation.
| Number of Participants | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- |
|---|---|---|---|---|
| M6: Treatment Failure- No | 33 | 52 | 39 | 59 |
| M6: Treatment Failure- Yes | 3 | 8 | 0 | 0 |
| M12: Treatment Failure- No | 29 | 42 | 36 | 56 |
| M12: Treatment Failure- Yes | 7 | 18 | 3 | 3 |
| M6: BPAR - No | 33 | 52 | 39 | 59 |
| M6: BPAR -Yes | 3 | 8 | 0 | 0 |
| M12: BPAR - No | 29 | 43 | 37 | 56 |
| M12: BPAR - Yes | 7 | 17 | 2 | 3 |
| M6: Graft Loss - No | 36 | 60 | 39 | 59 |
| M6: Graft Loss - Yes | 0 | 0 | 0 | 0 |
| M12: Graft Loss - No | 35 | 56 | 38 | 59 |
| M12: Graft Loss - Yes | 1 | 4 | 1 | 0 |
| M6: Death - No | 36 | 60 | 39 | 59 |
| M6: Death - Yes | 0 | 0 | 0 | 0 |
| M12: Death - No | 36 | 60 | 39 | 59 |
| M12: Death - Yes | 0 | 0 | 0 | 0 |
| M6: Loss to follow-up - No | 36 | 60 | 39 | 59 |
| M6: Loss to follow-up - Yes | 0 | 0 | 0 | 0 |
| M12: Loss to follow-up - No | 36 | 59 | 39 | 59 |
| M12: Loss to follow-up - Yes | 0 | 1 | 0 | 0 |
A biopsy proven acute rejection (BPAR) is defined as a biopsy graded IA, IB, IIA, IIB or III as per 2005/2007 Banff histological classification system. Biopsy graded IA: Significant interstitial infiltration (\> 25% of parenchyma) and foci of moderate tubulitis (\> 4 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IB: Significant interstitial infiltration (\> 25% of parenchyma) and foci of severe tubulitis (\> 10 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IIA: Mild to moderate intimal arteritis. Biopsy graded IIB: Severe intimal arteritis comprising \> 25% of the lumenal area. Biopsy graded III: Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation).
| Participants | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- |
|---|---|---|---|---|
| Cellular AR - No | 30 | 46 | 38 | 58 |
| Cellular AR - Yes | 6 | 14 | 1 | 1 |
A biopsy proven acute rejection (BPAR) is defined as a biopsy graded IA, IB, IIA, IIB or III as per 2005/2007 Banff histological classification system. Biopsy graded IA: Significant interstitial infiltration (\> 25% of parenchyma) and foci of moderate tubulitis (\> 4 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IB: Significant interstitial infiltration (\> 25% of parenchyma) and foci of severe tubulitis (\> 10 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IIA: Mild to moderate intimal arteritis. Biopsy graded IIB: Severe intimal arteritis comprising \> 25% of the lumenal area. Biopsy graded III: Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation).
| Participants | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- |
|---|---|---|---|---|
| M6: Banff type Grade IA | 0 | 2 | 0 | 0 |
| M6: Banff type Grade IB | 0 | 4 | 0 | 0 |
| M6: Banff type Grade IIA | 1 | 0 | 0 | 0 |
| M6: Banff type Grade IIB | 0 | 1 | 0 | 0 |
| M6: Banff type Grade III | 0 | 0 | 0 | 0 |
| M12: Banff type Grade IA | 2 | 7 | 1 | 0 |
| M12: Banff type Grade IB | 2 | 5 | 0 | 0 |
| M12: Banff type Grade IIA | 1 | 1 | 0 | 1 |
| M12: Banff type Grade IIB | 0 | 1 | 0 | 0 |
| M12: Banff type Grade III | 0 | 0 | 0 | 0 |
A biopsy proven acute rejection (BPAR) is defined as a biopsy graded IA, IB, IIA, IIB or III as per 2005/2007 Banff histological classification system.
| Number of participants | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- |
|---|---|---|---|---|
| M6 - No | 33 | 52 | 39 | 59 |
| M6 - Yes | 3 | 8 | 0 | 0 |
| M12 - No | 29 | 43 | 37 | 56 |
| M12 - Yes | 7 | 17 | 2 | 3 |
If a participant underwent a graft nephrectomy, then the day of nephrectomy was considered as the day of graft loss.
| Participants | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- |
|---|---|---|---|---|
| M6 - No | 36 | 60 | 39 | 59 |
| M6 - Yes | 0 | 0 | 0 | 0 |
| M12 - No | 35 | 56 | 38 | 59 |
| M12 - Yes | 1 | 4 | 1 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Neoral | — | 39/98 (39.8%) | 59/98 (60.2%) |
| Certican | — | 46/96 (47.9%) | 59/96 (61.5%) |
| Event | Neoral | Certican |
|---|---|---|
| PyrexiaGeneral disorders | 5/98 | 5/96 |
| Kidney transplant rejectionImmune system disorders | 0/98 | 4/96 |
| Urinary tract infectionInfections and infestations | 2/98 | 4/96 |
| Renal failure acuteRenal and urinary disorders | 4/98 | 2/96 |
| DiarrhoeaGastrointestinal disorders | 3/98 | 3/96 |
| PyelonephritisInfections and infestations | 2/98 | 3/96 |
| Pyelonephritis acuteInfections and infestations | 1/98 | 3/96 |
| Bacterial pyelonephritisInfections and infestations | 3/98 | 2/96 |
| Blood creatinine increasedInvestigations | 3/98 | 2/96 |
| AnaemiaBlood and lymphatic system disorders | 1/98 | 2/96 |
| Event | Neoral | Certican |
|---|---|---|
| Aphthous stomatitisGastrointestinal disorders | 3/98 | 17/96 |
| Oedema peripheralGeneral disorders | 17/98 | 14/96 |
| DyslipidaemiaMetabolism and nutrition disorders | 6/98 | 9/96 |
| Gingival hypertrophyGastrointestinal disorders | 8/98 | 0/96 |
| AnaemiaBlood and lymphatic system disorders | 6/98 | 7/96 |
| DiarrhoeaGastrointestinal disorders | 3/98 | 7/96 |
| Urinary tract infectionInfections and infestations | 5/98 | 7/96 |
| RashSkin and subcutaneous tissue disorders | 0/98 | 7/96 |
| LeukopeniaBlood and lymphatic system disorders | 7/98 | 2/96 |
| Cytomegalovirus infectionInfections and infestations | 7/98 | 2/96 |
| Age, Continuous(years) | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- | Total |
|---|---|---|---|---|---|
| Mean | 51.2 ± 10.7 | 46.4 ± 12.9 | 50.0 ± 10.0 | 50.7 ± 11.7 | 49.3 ± 11.7 |
| Sex: Female, Male(Participants) | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- | Total |
|---|---|---|---|---|---|
| Female | 17 | 17 | 16 | 16 | 66 |
| Male | 19 | 43 | 23 | 43 | 128 |
| BMI(kg/m^2) | Certican EMT+ | Certican EMT- | Neoral EMT+ | Neoral EMT- | Total |
|---|---|---|---|---|---|
| Mean | 24.3 ± 4.6 | 26.0 ± 4.6 | 25.6 ± 4.0 | 25.3 ± 4.2 | 25.4 ± 4.4 |
The record gives a start of Sep 2009, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus